Abstract:Abstract Background Malignant nephrosclerosis, defined as renal microangiopathy in the setting of severe hypertension, remains a critical renal emergency leading to end-stage renal disease despite aggressive anti-hypertensive treatment. Recently, activation of the complement alternative pathway (AP) has been reported to play a prominent role in the pathogenesis of malignant nephrosclerosis. However, subsequent study failed to recapitulate the findings of genetic complement abnormalities in the disease. This study aimed to determine the presence of AP activation and genetic complement defects and establish their correlations to renal microangiopathy lesions, clinical features and prognosis in patients with malignant nephrosclerosis. Methods Fifty patients with malignant hypertension and concomitant thrombotic microangiopathy (TMA) proven by renal biopsy were investigated; 25 cases of kidney donors who received zero-hour allograft biopsies were used as normal controls. Various renal TMA lesions in patients with malignant nephrosclerosis were reviewed and evaluated using a semi-quantitative scoring system. Deposition of C5b-9, C3a, C5a, C4d and mannose-binding lectin was assessed by immunohistochemistry. Co-localization of C5b-9 and CD34 was detected by confocal microscopy. Complement factor B (FB), factor P (FP; properdin), factor D (FD), factor H (FH), C3a and C5a levels were quantified by enzyme-linked immonosorbent assay in plasma and urine samples of patients with malignant nephrosclerosis and controls. Genetic abnormalities of complement components were analysed by whole-exome sequencing. Results Renal biopsies of malignant nephrosclerosis showed identical histopathological and ultrastructural features to atypical haemolytic uraemic syndrome. C5b-9, C3a and C5a deposits were found along the walls of arteries/arterioles and glomerular capillaries and localized in the endothelial cells. Elevated plasma and urinary levels of FB, FP, FD, C3a and C5a as well as decreased FH levels were observed in patients with malignant nephrosclerosis compared with normal controls. The urinary levels of complement AP components, but not the plasma levels, were correlated with renal functions, prognosis and active TMA lesions except for arteriolar thrombi. Finally, mutations of the MCP, CFB, CFH and CFHR5 genes were identified in 8 of 20 patients with malignant nephrosclerosis. Conclusions Aberrant complement AP dysregulation was demonstrated and associated with the activity, severity and renal outcomes of malignant nephrosclerosis. This observation warrants screening for complement defects in patients with malignant nephrosclerosis for the potential use of complement regulators and also highlights the need for further investigation of the precise role of AP in the pathogenesis of the disease.

Differential Contributions of the C5b-9 and C5a/C5aR Pathways to Microvascular and Macrovascular Thrombosis in Complement-Mediated Thrombotic Microangiopathy Patients.

#5524 THE ROLE OF C5AR VERSUS C3 IN THROMBOTIC MICROANGIOPATHY, ISCHEMIC KIDNEY NECROSIS, AND ACUTE KIDNEY INJURY INDUCED BY CHOLESTEROL CRYSTAL EMBOLISM

Clinical value of the renal pathologic scoring system in complement-mediated thrombotic microangiopathy

Evaluation the Risk Factor of Transplantation-Associated Thrombotic Microangiopathy.

Association between thrombotic microangiopathy and activated alternative complement pathway in malignant nephrosclerosis

Kidney thrombotic microangiopathy with concurrent monoclonal gammopathy

The Spectrum of Renal Thrombotic Microangiopathy in Lupus Nephritis

Thrombotic microangiopathy mediates poor prognosis among lupus nephritis via complement lectin and alternative pathway activation

[Clinical characteristics and genetic profile of complement system in renal thrombotic microangiopathy in patients with severe forms of arterial hypertension]

Upregulation of HIF-1α contributes to complement activation in transplantation-associated thrombotic microangiopathy

Assessment of epidemiology and outcomes of adult patients with kidney-limited thrombotic microangiopathies.

Potential Involvement of Complement Activation in Kidney Vascular Lesions of Arterionephrosclerosis

Complement C5-inhibiting therapy for the thrombotic microangiopathies: accumulating evidence, but not a panacea

Complement Mediated Endothelial Damage in Thrombotic Microangiopathies

Thrombotic microangiopathies assessment: mind the complement

Clinical and Renal Biopsy Findings Predicting Outcome in Renal Thrombotic Microangiopathy: A Large Cohort Study from a Single Institute in China

The Role of Complement in Microangiopathic Lesions of IgA Nephropathy

The spectrum of thrombotic microangiopathy related to monoclonal gammopathy

Thrombotic Microangiopathies and the Kidney

Clinico-pathological Characteristics and Outcome of Patients with Thrombotic Microangiopathy

P0403INNATE DEFECTS OF COMPLEMENT ALTERNATIVE PATHWAY AMONG LUPUS PATIENTS WITH AND WITHOUT THROMBOTIC MICROANGIOPATHY